Predilife S.A. develops and sells medical techniques and mathematical models. The company provides prevention and breast check-up tests. Its products include MammoRisk, a test for predicting the development of breast cancer based on the patient's individual risk; and DenSeeMammo, a breast density measurement software, as well as a medical device for the prediction of prostate cancer risk. Predilife S.A. was founded in 2004 and is headquartered in Villejuif, France.
Stock data | 2024 | Change |
---|---|---|
Price | $5.54 | N/A |
Market Cap | $20.15M | N/A |
Shares Outstanding | 3.64M | N/A |
Employees | 20.00 | N/A |